Find the Perfect Plan for Your Investment Journey
H
Latest price
52 Week Range
DKK27.20 - DKK49.38
Next Earnings Date
May 14 2025
Next Earnings Date
May 14 2025
Latest price
Market Cap | DKK28.45B |
EV | DKK40.48B |
Shares Outstanding | 991.23M |
Beta | 0.27 |
Analyst Rating | HOLD |
Analyst Target Price | DKK49.68 |
P/E 2025E | 6.10x |
P/Revenue 2025E | 1.20x |
Revenue | 10.50% |
EPS | 58.80% |
Operating Cash Flow | 13.60% |
Free Cash Flow | 18.40% |
Revenue | 5.10% |
EPS | 2.30% |
Operating Cash Flow | 24.80% |
Free Cash Flow | 29.90% |
Gross Margin 2025E | 82.98% |
Net Profit Margin 2025E | 14.54% |
ROE 2025E | 15.26% |
ROCE 2024 | 13.36% |
DPS 2025E | DKK1.04 |
Payout Ratio 2025E | 21.49% |
Div. Yield 2025E | 3.54% |
DPS Last 3Y CAGR | 33.40% |
Price
%
1M
3M
6M
1Y
3Y
5Y
H
H. Lundbeck A/S
HLUN B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
van Zyl, Charl
Employees
5,707
Website
www.lundbeck.comIPO Date
2022-06-10
Headquarters
Ottiliavej 9, Valby, Capital Region of Denmark, 2500, Denmark
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved